Skip to main content
. 2022 Aug 11;28(11):1546–1551. doi: 10.1016/j.jiac.2022.08.007

Table 3.

The number of participants with post COVID-19 condition in the Omicron group (n = 53).

Symptoms Numbera (%b) Lasting at least 2 months within 3 months since the onset (%b)
Fatigue 22 (41.5) 3 (5.7)
SoB 10 (18.9) 2 (3.8)
Cough 23 (43.4) 2 (3.8)
Dysosmia 3 (5.7) 0 (0.0)
Dysgeusia 7 (13.2) 0 (0.0)
Hair loss 2 (3.8) 0 (0.0)
Depressed mood 5 (9.4) 2 (3.8)
Brain fog 0 (0.0) 0 (0.0)
LoC 8 (15.1) 3 (5.7)
MD 3 (5.7) 1 (1.9)
At least one symptomc 41 (77.4) 7 (13.2)



Other symptoms
Fever 45 (84.9) 0 (0.0)
Sore throat 30 (56.6) 0 (0.0)
Sputum 19 (35.8) 2 (3.8)
Runny nose 15 (28.3) 0 (0.0)
Headache 10 (18.9) 1 (1.9)
Muscle pain 1 (1.9) 0 (0.0)
Joint pain 7 (13.2) 0 (0.0)
Chest pain 3 (5.7) 1 (1.9)
Palpitation 1 (1.9) 1 (1.9)
Abdominal pain 4 (7.5) 0 (0.0)
Diarrhea 6 (11.3) 0 (0.0)
Appetite loss 3 (5.7) 0 (0.0)

Abbreviations: SoB, shortness of breath; LoC, loss of concentration; MD, memory disturbance.

a

Number of patients experiencing each symptom within 3 months since the onset.

b

Calculated by dividing the number of patients by the total number of participants (n = 53).

c

At least one symptom of fatigue, shortness of breath, cough, dysosmia, dysgeusia, hair loss, depressed mood, brain fog, loss of concentration, and memory disturbance (not including other symptoms).